Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2026-02-24 @ 2:08 PM
Study NCT ID:
NCT02210858
Status:
COMPLETED
Last Update Posted:
2018-06-04
First Post:
2014-08-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Accelerated Phase of Disease | View |
| None | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | View |
| None | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Chronic Myelomonocytic Leukemia | View |
| None | Chronic Phase of Disease | View |
| None | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | View |
| None | Recurrent Disease | View |
Keywords: